Zobrazeno 1 - 10
of 10
pro vyhledávání: '"DiLoreto K"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Kniha
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Herd P; Lafollette School of Public Affairs, University of Wisconsin-Madison., Schaeffer NC; Lafollette School of Public Affairs, University of Wisconsin-Madison., DiLoreto K; Lafollette School of Public Affairs, University of Wisconsin-Madison., Jacques K; Lafollette School of Public Affairs, University of Wisconsin-Madison., Stevenson J; Lafollette School of Public Affairs, University of Wisconsin-Madison., Rey F; Lafollette School of Public Affairs, University of Wisconsin-Madison., Roan C; Lafollette School of Public Affairs, University of Wisconsin-Madison.
Publikováno v:
The journals of gerontology. Series B, Psychological sciences and social sciences [J Gerontol B Psychol Sci Soc Sci] 2017 Dec 15; Vol. 73 (1), pp. 124-133.
Autor:
Dallas S; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)., Salphati L; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.) salphati.laurent@gene.com., Gomez-Zepeda D; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)., Wanek T; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)., Chen L; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)., Chu X; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)., Kunta J; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)., Mezler M; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)., Menet MC; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)., Chasseigneaux S; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)., Declèves X; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)., Langer O; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)., Pierre E; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)., DiLoreto K; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)., Hoft C; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)., Laplanche L; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)., Pang J; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)., Pereira T; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)., Andonian C; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)., Simic D; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)., Rode A; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)., Yabut J; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)., Zhang X; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.)., Scheer N; DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., C.H., L.L.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (L.S., J.P., X.Z.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., C.A., E.P.); Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (T.W., O.L.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria (O.L.), Preclinical Development and Safety, Janssen Research and Development, LLC, Spring House, PA (S.D., J.K., K.D., D.S.). Merck Sharp and Dohme Corporation, Whitehouse Station, New Jersey (X.C., T.P., J.Y.); Université Paris Descartes, UMR-S 1144, Paris, France (D.G.-Z., M.-C.M., S.C., X.D.); Taconic Biosciences GmbH, Koeln, Germany (A.R., N.S.).
Publikováno v:
Molecular pharmacology [Mol Pharmacol] 2016 May; Vol. 89 (5), pp. 492-504. Date of Electronic Publication: 2016 Feb 18.